AN2 Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Menlo Park, CA
SEC filing record 1 source field available
Fiscal year end
31 December
AN2 Therapeutics, Inc. has filed 377 SEC EDGAR filings since 24 Sep 2021

SEC filing history

Showing 276-300 of 377 matching filings.

Per page
25
Current page
12
S-3 File 333-271174

S-3

Filing date
06 Apr 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-270962

S-8

Filing date
30 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
24 Feb 2023
Reporting date
23 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-93617

SC 13G/A

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-93617

AMENDMENT NO. 1 TO THE SCHEDULE 13G

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-93617

SC 13G/A

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

SC 13G AN2 THERAPEUTICS

Filing date
13 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

SC 13G

Filing date
13 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-93617

SC 13G

Filing date
10 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Nov 2022
Reporting date
10 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
09 Nov 2022
Reporting date
08 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
07 Nov 2022
Reporting date
03 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
02 Nov 2022
Reporting date
31 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Oct 2022
Reporting date
27 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Oct 2022
Reporting date
14 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .